Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2562 0.0586%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: London
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

GW Pharmaceuticals PLC

Add to Portfolio

GWP:LN

79.0000 GBp 0.5000 0.64%

As of 11:35:28 ET on 05/25/2012.

Snapshot for GW Pharmaceuticals PLC (GWP)

Open: 80.0000 Day's Range: 78.0000 - 80.0000 Volume: 26,884 Bid: 78.0000
Previous Close: 78.5000 52wk Range: 73.5000 - 133.0000 1-Yr Rtn: -36.80% Ask: 80.0000

Stock Chart for GWP

No chart data available.
  • GWP:LN 79.0000
  • 1D
  • 1M
  • 1Y
78.5000
Interactive GWP Chart

Previous Close

Key Statistics for GWP

Current P/E Ratio (ttm) -
Estimated P/E (09/2012) 32.9167
Earnings Per Share (GBP) (ttm) -0.0280
Est. EPS (GBP) (09/2012) 0.0240
Est. PEG Ratio -
Market Cap (M GBP) 105.11
Shares Outstanding (M) 133.06
Enterprise Value (M GBP) (ttm) 78.90
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 6.9836
Price/Sale (ttm) 4.3447
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 11/22/2012
More GWP Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for GWP

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)
More GWP Income Statement Data
  • Total Assets
  • Total Liabilities (M/GBP)
  • Debt to Assets (%)
More GWP Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/GBP)
More GWP Cash Flow Data

Company Profile & Key Executives for GWP

GW Pharmaceuticals plc researches and develops cannabinoid prescription medicines for the treatment of cancer pain, Multiple Sclerosis, and neuropathic pain.

Geoffrey William GuyChairman/FounderJames J NobleDeputy Chairman
David KirkFinance DirectorJustin David GoverManaging Director
More Company Profile & Key Executives for GWP

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements